Company Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
5.640 ^USD	-1.57%		-8.59%	-40.13%

Jun. 03	Amicus Therapeutics Announces New Analysis of Pombiliti (Cipaglucosidase Alfa-atga) + Opfolda®? Published in Muscle and Nerve	CI
May. 14	Amicus Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:00 AM

Business description: Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.

Number of employees: 499

Sales by Activity: Amicus Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Discovery, Development and Commercialization of Advanced Therapies	261M	306M	329M	399M	528M

See all business segments

Geographical breakdown of sales: Amicus Therapeutics, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Ex-U.S.	181M	210M	213M	252M	322M
United States	80.05M	95.39M	116M	147M	206M

See all geographic segments

Executive Committee: Amicus Therapeutics, Inc.

Manager	Title	Age	Since
Bradley Campbell CEO	Chief Executive Officer	49	2022-07-31
Simon Harford DFI	Director of Finance/CFO	64	2023-08-20
Pat O’Sullivan COO	Chief Operating Officer	-	2022-06-30
Jill Weimer CTO	Chief Tech/Sci/R&D Officer	-	-
Patrik Florencio CMP	Compliance Officer	-	2015-07-31

See AMICUS THERAPEUTICS, INC. governance

Composition of the Board of Directors: Amicus Therapeutics, Inc.

Director	Title	Age	Since
Mike Raab CHM	Chairman	60	2024-03-03
Glenn Sblendorio BRD	Director/Board Member	69	2006-05-31
Bradley Campbell BRD	Director/Board Member	49	2018-06-07
Margaret McGlynn BRD	Director/Board Member	65	2009-09-30
Craig Wheeler BRD	Director/Board Member	64	2016-06-09
Lynn Bleil BRD	Director/Board Member	61	2018-09-10
Burke Whitman BRD	Director/Board Member	69	2019-06-26
Michael Kelly BRD	Director/Board Member	68	2020-11-30
Eiry Roberts BRD	Director/Board Member	61	2021-06-09

Composition of the Board of Directors

Shareholders: Amicus Therapeutics, Inc.

Name	Equities	%	Valuation
Wellington Trust Co., NA 9.504 %	29,200,617	9.504 %	177 M $
Vanguard Fiduciary Trust Co. 9.455 %	29,050,621	9.455 %	176 M $
BlackRock Advisors LLC 8.455 %	25,977,844	8.455 %	158 M $
Perceptive Advisors LLC 6.986 %	21,464,527	6.986 %	130 M $
Avoro Capital Advisor LLC 6.672 %	20,500,000	6.672 %	124 M $

List of AMICUS THERAPEUTICS, INC. shareholders

Company details: Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc.

47 Hulfish Street

08542, Princeton

+609 662 2000

http://www.amicusrx.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
AMICUS THERAPEUTICS, INC.	-1.57%	-8.59%	-42.27%	-39.68%	1.76B
LONZA GROUP AG	+0.39%	-3.98%	+18.34%	+12.67%	48.12B
BEONE MEDICINES LTD.	-2.25%	-10.65%	+59.72%	+86.98%	29.99B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-40.00%	+136.59%	+35,225.28%	+3,297.09%	31.33B
IQVIA HOLDINGS INC.	+0.08%	-2.77%	-27.30%	-21.44%	26.75B
CELLTRION, INC.	+1.25%	-1.04%	-3.42%	+20.40%	25.65B
EUROFINS SCIENTIFIC SE	+0.10%	-1.52%	+13.51%	-19.20%	12.25B
TEMPUS AI, INC.	-1.14%	-4.10%	+125.22%	-	11.96B
ICON PUBLIC LIMITED COMPANY	+2.02%	-0.41%	-54.03%	-27.08%	11.41B
ASCENDIS PHARMA A/S	+3.63%	+3.50%	+43.60%	+110.80%	10.31B
Average	-0.34%	+26.27%	+3,535.86%	+380.06%	20.95B
Weighted average by Cap.	-0.85%	+40.51%	+5,282.18%	+541.51%